{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137044528662912.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/ajh.24015"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fajh.24015"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.24015"}}],"dc:title":[{"@value":"Durable remission with rituximab in a patient with an unusual variant of <scp>C</scp>astleman's disease with myelofibrosis—<scp>TAFRO</scp> syndrome"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137044528662913","@type":"Researcher","foaf:name":[{"@value":"Preetesh Jain"}],"jpcoar:affiliationName":[{"@value":"Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Houston Texas"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044528662916","@type":"Researcher","foaf:name":[{"@value":"Srdan Verstovsek"}],"jpcoar:affiliationName":[{"@value":"Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Houston Texas"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044528662912","@type":"Researcher","foaf:name":[{"@value":"Sanam Loghavi"}],"jpcoar:affiliationName":[{"@value":"Departments of Hematopathology, The University of Texas, M.D. Anderson Cancer Center Houston Texas"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044528662915","@type":"Researcher","foaf:name":[{"@value":"Jeffrey L. Jorgensen"}],"jpcoar:affiliationName":[{"@value":"Departments of Hematopathology, The University of Texas, M.D. Anderson Cancer Center Houston Texas"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044528662919","@type":"Researcher","foaf:name":[{"@value":"Keyur P. Patel"}],"jpcoar:affiliationName":[{"@value":"Departments of Hematopathology, The University of Texas, M.D. Anderson Cancer Center Houston Texas"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044528662914","@type":"Researcher","foaf:name":[{"@value":"Zeev Estrov"}],"jpcoar:affiliationName":[{"@value":"Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Houston Texas"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044528662917","@type":"Researcher","foaf:name":[{"@value":"Luis Fayad"}],"jpcoar:affiliationName":[{"@value":"Lymphoma and Myeloma The University of Texas, M.D. Anderson Cancer Center Houston Texas"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044528662918","@type":"Researcher","foaf:name":[{"@value":"Naveen Pemmaraju"}],"jpcoar:affiliationName":[{"@value":"Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Houston Texas"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03618609"},{"@type":"EISSN","@value":"10968652"}],"prism:publicationName":[{"@value":"American Journal of Hematology"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2015-04-29","prism:volume":"90","prism:number":"11","prism:startingPage":"1091","prism:endingPage":"1092"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fajh.24015"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.24015"}],"createdAt":"2015-03-24","modifiedAt":"2023-09-24","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050012570392864000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Idiopathic multicentric Castleman’s disease: a clinicopathologic study in comparison with IgG4-related disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204876296960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Remission of Refractory Ascites and Discontinuation of Hemodialysis after Additional Rituximab to Long-term Glucocorticoid Therapy in a Patient with TAFRO Syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204876624512","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two Cases of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with High Serum Procalcitonin Levels, Including the First Case Complicated with Adrenal Hemorrhaging"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679629135488","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390292561171578752","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"International definition of iMCD-TAFRO: future perspectives"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/ajh.24015"},{"@type":"CROSSREF","@value":"10.3960/jslrt.21037_references_DOI_Ai9ABVJgTkpYOUD28Tn04v5EnSR"},{"@type":"CROSSREF","@value":"10.18632/oncotarget.24068_references_DOI_Ai9ABVJgTkpYOUD28Tn04v5EnSR"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.56.7991_references_DOI_Ai9ABVJgTkpYOUD28Tn04v5EnSR"},{"@type":"CROSSREF","@value":"10.2177/jsci.39.64_references_DOI_Ai9ABVJgTkpYOUD28Tn04v5EnSR"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.0116-17_references_DOI_Ai9ABVJgTkpYOUD28Tn04v5EnSR"}]}